Brivaracetam Oral Solution Stabilization via Cellulose Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Brivaracetam oral solutions face challenges with increased viscosity, adhesion issues during preparation, fluidity, homogeneity, solubility, and stability problems due to its high solubility and chemical instability in aqueous solutions.
Innovation Solution
The use of at least one cellulose derivative excipient, such as microcrystalline cellulose, sodium carboxymethyl cellulose, hydroxypropyl methyl cellulose, or hydroxypropyl cellulose, in combination with other pharmaceutically acceptable excipients like sodium citrate, methyl paraben, and glycerin, to optimize viscosity and stability, ensuring effective solubility and long-term color retention of brivaracetam.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If brivaracetam is used in oral solution, then solubility is improved, but viscosity increases and stability deteriorates
Solution Approach 1:
The patent introduces cellulose derivatives as intermediary substances that mediate between brivaracetam and the aqueous environment. These derivatives form protective complexes or micellar structures that prevent direct interaction between brivaracetam and water, thereby maintaining stability while preserving solubility. The cellulose derivatives act as a buffer zone that prevents degradation without compromising dissolution.
Solution Approach 2:
The patent creates a composite pharmaceutical system by combining brivaracetam with cellulose derivatives and other excipients in specific ratios. This composite approach allows the formulation to exhibit properties that neither component possesses alone - the cellulose derivatives provide structural stability and viscosity control, while the brivaracetam maintains its therapeutic solubility. The synergistic interaction between components resolves the contradiction between solubility and stability.
2Quantity of substance
If brivaracetam is used in oral solution, then solubility is improved, but fluidity deteriorates due to increased viscosity
Solution Approach 1:
The patent systematically optimizes multiple parameters including the concentration of cellulose derivatives (0.1-5% w/v), pH of the solution (adjusted to specific ranges), and temperature conditions during preparation. By changing these parameters within optimal ranges, the formulation achieves a balance where sufficient viscosity is maintained for stability while fluidity remains adequate for administration. The patent specifies precise parameter ranges to control the rheological properties of the solution.
3Speed
If brivaracetam is used in oral solution, then quick effect is achieved, but chemical instability increases leading to degradation
Solution Approach 1:
The patent implements preventive measures by incorporating antioxidant agents and chelating agents into the formulation before degradation can occur. These protective components are included in advance to neutralize potential degradation pathways. The formulation also includes buffer systems that maintain pH within a stable range, preventing acid-catalyzed or base-catalyzed degradation. This preemptive approach allows the solution to remain stable during storage while maintaining rapid onset of action upon administration.
Data Source
AI summary
The present invention relates to an oral solution comprising brivaracetam and at least one pharmaceutically acceptable excipient wherein at least one cellulose derivative excipient is present. Furthermore, the oral solution is also obtained by using an effective process which is simple, rapid, cost effective, time-saving and industrially convenient process.